Review




Structured Review

Dexcom Inc dexcom g6 sensor
Dexcom G6 Sensor, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dexcom+sensor/dexcom+g6+sensor/pmc10890954-18-20-20
Average 86 stars, based on 1 article reviews
dexcom g6 sensor - by Bioz Stars, 2026-10
86/100 stars

Images

Related Articles

Food & Beverages:

Article Title: Clinical accuracy of Dexcom G6 and G7 continuous glucose monitors in hospitalized pediatric patients with type 1 diabetes: a real-world study.
Article Snippet: Dexcom G6 and G7 sensors (Dexcom Inc., San Diego, CA, USA) provided factory-calibrated interstitial glucose readings at 5-min intervals and stored the values on a receiver or smartphone application.14 Raw sensor files were exported from Dexcom Clarity (a Cloud platform) as commaseparated value (CSV) files.15 Reference BG values were obtained using the BAROzen H Expert Plus BG monitoring system (Handok, Seoul, Korea), which employs a glucose dehydrogenase-flavin adenine dinucleotide enzymatic method and meets the ISO 15197:2013 performance criteria.16 All BG readings were automatically transmitted to the hospital electronic medical records.

Article Title: Clinical accuracy of Dexcom G6 and G7 continuous glucose monitors in hospitalized pediatric patients with type 1 diabetes: a real-world study.
Article Snippet: Of these, 1,106 pairs (59.9%) from Dexcom G6 sensors and 740 (40.1%) from G7 sensors.

Article Title: Maternal Hypoglycemia and Reduced Foetal Growth in Pregnancies Following Roux-en-Y Gastric Bypass: A Prospective Cohort Study.
Article Snippet: We applied the Dexcom G6 sensor (Dexcom Inc., San Diego, CA) in gestational week 12–14 (first trimester), 24 (second trimester), 34 (third trimester) and 4–6 weeks postpartum.

Article Title: First in Human Feasibility Study of an Insulin Patch Pump Combined With CGM-Insulin Delivery Cannula
Article Snippet: Following written informed consent, all participants were provided with and educated in the use of a study blood glucose meter (BGM): Ascensia Contour Next meter (Ascensia Diabetes Care, Baulkham Hills, AU) and a Dexcom G6 sensor (Dexcom, San Diego, California) inserted into the abdomen or flank.

Article Title: [Automated insulin delivery (AID) systems, physical activity and sports in type 1 diabetes mellitus: joint guidelines of the DDG and ÖDG].
Article Snippet: Accuracy of the Dexcom G6 Glucose Sensor duringAerobic, Resistance, and Interval Exercise in AdultswithType1Diabetes.Biosens.2020;10.

Article Title: Clinical accuracy of Dexcom G6 and G7 continuous glucose monitors in hospitalized pediatric patients with type 1 diabetes: a real-world study.
Article Snippet: In conclusion, Dexcom G6 and G7 sensors rapidly achieved inpatient benchmarks in pediatric inpatients with T1D.

Clinical Proteomics:

Article Title: Clinical accuracy of Dexcom G6 and G7 continuous glucose monitors in hospitalized pediatric patients with type 1 diabetes: a real-world study.
Article Snippet: Dexcom G6 and G7 sensors (Dexcom Inc., San Diego, CA, USA) provided factory-calibrated interstitial glucose readings at 5-min intervals and stored the values on a receiver or smartphone application.14 Raw sensor files were exported from Dexcom Clarity (a Cloud platform) as commaseparated value (CSV) files.15 Reference BG values were obtained using the BAROzen H Expert Plus BG monitoring system (Handok, Seoul, Korea), which employs a glucose dehydrogenase-flavin adenine dinucleotide enzymatic method and meets the ISO 15197:2013 performance criteria.16 All BG readings were automatically transmitted to the hospital electronic medical records.

Article Title: Clinical accuracy of Dexcom G6 and G7 continuous glucose monitors in hospitalized pediatric patients with type 1 diabetes: a real-world study.
Article Snippet: Of these, 1,106 pairs (59.9%) from Dexcom G6 sensors and 740 (40.1%) from G7 sensors.

Article Title: Maternal Hypoglycemia and Reduced Foetal Growth in Pregnancies Following Roux-en-Y Gastric Bypass: A Prospective Cohort Study.
Article Snippet: We applied the Dexcom G6 sensor (Dexcom Inc., San Diego, CA) in gestational week 12–14 (first trimester), 24 (second trimester), 34 (third trimester) and 4–6 weeks postpartum.

Article Title: First in Human Feasibility Study of an Insulin Patch Pump Combined With CGM-Insulin Delivery Cannula
Article Snippet: Following written informed consent, all participants were provided with and educated in the use of a study blood glucose meter (BGM): Ascensia Contour Next meter (Ascensia Diabetes Care, Baulkham Hills, AU) and a Dexcom G6 sensor (Dexcom, San Diego, California) inserted into the abdomen or flank.

Article Title: [Automated insulin delivery (AID) systems, physical activity and sports in type 1 diabetes mellitus: joint guidelines of the DDG and ÖDG].
Article Snippet: Accuracy of the Dexcom G6 Glucose Sensor duringAerobic, Resistance, and Interval Exercise in AdultswithType1Diabetes.Biosens.2020;10.

Article Title: Clinical accuracy of Dexcom G6 and G7 continuous glucose monitors in hospitalized pediatric patients with type 1 diabetes: a real-world study.
Article Snippet: In conclusion, Dexcom G6 and G7 sensors rapidly achieved inpatient benchmarks in pediatric inpatients with T1D.

Biomarker Discovery:

Article Title: Clinical accuracy of Dexcom G6 and G7 continuous glucose monitors in hospitalized pediatric patients with type 1 diabetes: a real-world study.
Article Snippet: Dexcom G6 and G7 sensors (Dexcom Inc., San Diego, CA, USA) provided factory-calibrated interstitial glucose readings at 5-min intervals and stored the values on a receiver or smartphone application.14 Raw sensor files were exported from Dexcom Clarity (a Cloud platform) as commaseparated value (CSV) files.15 Reference BG values were obtained using the BAROzen H Expert Plus BG monitoring system (Handok, Seoul, Korea), which employs a glucose dehydrogenase-flavin adenine dinucleotide enzymatic method and meets the ISO 15197:2013 performance criteria.16 All BG readings were automatically transmitted to the hospital electronic medical records.

Article Title: Clinical accuracy of Dexcom G6 and G7 continuous glucose monitors in hospitalized pediatric patients with type 1 diabetes: a real-world study.
Article Snippet: Of these, 1,106 pairs (59.9%) from Dexcom G6 sensors and 740 (40.1%) from G7 sensors.

Article Title: Maternal Hypoglycemia and Reduced Foetal Growth in Pregnancies Following Roux-en-Y Gastric Bypass: A Prospective Cohort Study.
Article Snippet: We applied the Dexcom G6 sensor (Dexcom Inc., San Diego, CA) in gestational week 12–14 (first trimester), 24 (second trimester), 34 (third trimester) and 4–6 weeks postpartum.

Article Title: First in Human Feasibility Study of an Insulin Patch Pump Combined With CGM-Insulin Delivery Cannula
Article Snippet: Following written informed consent, all participants were provided with and educated in the use of a study blood glucose meter (BGM): Ascensia Contour Next meter (Ascensia Diabetes Care, Baulkham Hills, AU) and a Dexcom G6 sensor (Dexcom, San Diego, California) inserted into the abdomen or flank.

Article Title: [Automated insulin delivery (AID) systems, physical activity and sports in type 1 diabetes mellitus: joint guidelines of the DDG and ÖDG].
Article Snippet: Accuracy of the Dexcom G6 Glucose Sensor duringAerobic, Resistance, and Interval Exercise in AdultswithType1Diabetes.Biosens.2020;10.

Article Title: Clinical accuracy of Dexcom G6 and G7 continuous glucose monitors in hospitalized pediatric patients with type 1 diabetes: a real-world study.
Article Snippet: In conclusion, Dexcom G6 and G7 sensors rapidly achieved inpatient benchmarks in pediatric inpatients with T1D.



Similar Products

86
Dexcom Inc dexcom cgm sensor
Dexcom Cgm Sensor, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dexcom+sensor/cgm+sensors/pm42156180-52-2-2
Average 86 stars, based on 1 article reviews
dexcom cgm sensor - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

86
Dexcom Inc dexcom g7 cgm sensor
Dexcom G7 Cgm Sensor, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dexcom+sensor/dexcom+g7+sensor/pm42156180-106-2-2
Average 86 stars, based on 1 article reviews
dexcom g7 cgm sensor - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

86
Dexcom Inc dexcom g4 platinum sensor
Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG trial (Dexcom <t>G4</t> Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.
Dexcom G4 Platinum Sensor, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dexcom+sensor/dexcom+g4+platinum/med_rxiv__64898__2026__05__13__26353094-140-16-16
Average 86 stars, based on 1 article reviews
dexcom g4 platinum sensor - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

86
Dexcom Inc dexcom sensors
Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG trial (Dexcom <t>G4</t> Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.
Dexcom Sensors, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dexcom+sensor/dexcom+sensors/med_rxiv__64898__2026__05__13__26353094-32-26-26
Average 86 stars, based on 1 article reviews
dexcom sensors - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

86
Dexcom Inc dexcom g6 sensor
Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG trial (Dexcom <t>G4</t> Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.
Dexcom G6 Sensor, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dexcom+sensor/dexcom+g6+sensor/pm42108404-47-3-6
Average 86 stars, based on 1 article reviews
dexcom g6 sensor - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

86
Dexcom Inc unblinded dexcom g7 sensor
Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG trial (Dexcom <t>G4</t> Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.
Unblinded Dexcom G7 Sensor, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dexcom+sensor/dexcom+g7+sensor/pm42092238-19-34-35
Average 86 stars, based on 1 article reviews
unblinded dexcom g7 sensor - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

86
Dexcom Inc dexcom g7 sensor
Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG trial (Dexcom <t>G4</t> Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.
Dexcom G7 Sensor, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dexcom+sensor/dexcom+g7+sensor/pmc13128380-112-1-1
Average 86 stars, based on 1 article reviews
dexcom g7 sensor - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

86
Dexcom Inc dexcom sensor
Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG trial (Dexcom <t>G4</t> Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.
Dexcom Sensor, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dexcom+sensor/dexcom+sensor/pmc13065641-82-22-22
Average 86 stars, based on 1 article reviews
dexcom sensor - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

86
Dexcom Inc dexcom g4 sensor
Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG trial (Dexcom <t>G4</t> Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.
Dexcom G4 Sensor, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dexcom+sensor/dexcom+g4+sensor/pmc13065641-63-9-9
Average 86 stars, based on 1 article reviews
dexcom g4 sensor - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

Image Search Results


Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG trial (Dexcom G4 Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.

Journal: medRxiv

Article Title: Prevalence, duration, and clinical implications of Continuous Glucose Monitor (CGM) measurement limit capping in type 1 diabetes

doi: 10.64898/2026.05.13.26353094

Figure Lengend Snippet: Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG trial (Dexcom G4 Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.

Article Snippet: Our BGM comparison is restricted to a single arm of a single trial using the older Dexcom G4 Platinum sensor (mean absolute relative difference (MARD) ∼14%), which has lower accuracy than the Dexcom G6 (MARD ∼9%) used in three of our four datasets.

Techniques: Software